Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Allogeneic peripheral blood stem cell transplantation in 23 adult patientswith hematologic malignancies: A single-center experience
Autore:
Takenaka, K; Shinagawa, K; Sunami, K; Fujii, N; Hiramatsu, Y; Maeda, Y; Nawa, Y; Katayama, Y; Teshima, T; Ishimaru, F; Kiura, K; Ikeda, K; Harada, M;
Indirizzi:
Okayama Univ, Sch Med, Dept Internal Med 2, Okayama 7008558, Japan OkayamaUniv Okayama Japan 7008558 nternal Med 2, Okayama 7008558, Japan
Titolo Testata:
INTERNATIONAL JOURNAL OF HEMATOLOGY
fascicolo: 3, volume: 72, anno: 2000,
pagine: 362 - 370
SICI:
0925-5710(200010)72:3<362:APBSCT>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
VERSUS-HOST DISEASE; COLONY-STIMULATING FACTOR; BONE-MARROW TRANSPLANTATION; PROGENITOR-CELL; NORMAL DONORS; MONONUCLEAR-CELLS; ACUTE GVHD; RHG-CSF; MOBILIZATION; ENGRAFTMENT;
Keywords:
allogeneic peripheral blood stem cell transplantation; hematologic malignancies; graft-versus-host disease; regimen-related toxicity; graft-versus-leukemia effect;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
50
Recensione:
Indirizzi per estratti:
Indirizzo: Takenaka, K Okayama Univ, Sch Med, Dept Internal Med 2, 2-5-1 Shikata-cho,Okayama 7008558, Japan Okayama Univ 2-5-1 Shikata-cho Okayama Japan 7008558 8, Japan
Citazione:
K. Takenaka et al., "Allogeneic peripheral blood stem cell transplantation in 23 adult patientswith hematologic malignancies: A single-center experience", INT J HEMAT, 72(3), 2000, pp. 362-370

Abstract

We describe a single-center experience of 23 consecutive patients (median age, 35 years) with hematologic malignancies who received allogeneic peripheral blood stem cell transplants (alloPBSCTs) from HLA-identical siblings. Ten patients had standard-risk disease and 13 had high-risk disease. Twenty-one patients received alloPBSCT as a primary transplant, and the remaining2, with high-risk disease, as a second transplant after posttransplantation relapse. All donors received daily subcutaneous injections of granulocytecolony-stimulating factor at a dose of 10 mug/kg, and peripheral blood stem cells were collected by 1 to 3 aphereses. Median numbers of CD34(+) and CD3(+) cells infused were 5.8 x 10(6)/kg (range, 1.3-19.7 x 10(6)/kg) and 4.9 x 10(8)/kg (range, 1.9-8.6 x 10(8)/kg), respectively. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A (CyA) and methotrexate(18 patients) or CyA and methylprednisolone (5 patients). Rapid hematologic engraftment was observed in 20 of the 23 patients. Median days to absolute neutrophil counts >0.5 x 10(9)/L and platelet counts >20 x 10(9)/L were 12 (range, 9-18 days) and 14 (range, 10-128 days), respectively. Acute GVHD of grade 2-4 was observed in 6 of 20 evaluable patients (30%) and extensivechronic GVHD in 8 of 15 evaluable patients (53%). Ten of the 23 patients (44%) were surviving in continuous complete remission 191 to 1492 days (median, 643 days) posttransplantation. Treatment-related death within 100 days posttransplantation was observed in 6 of the 23 patients (26%). Six of the 23 patients (26%) developed relapse at a median 81 days (range, 38-160 days) posttransplantation. Further study is needed to assess the precise benefits of alloPBSCT compared with allogeneic bone marrow transplantation. Int JHematol. 2000;72:362-370. (C) 2000 The Japanese Society of Hematology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 08:10:13